Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease

Journal of Clinical Investigation

Volumn 113, Issue 4, 2004, Pages 528-538

  Chan, Iris T ^a   Kutok, Jeffery L ^a   Williams, Ifor R ^b   Cohen, Sarah ^a   Kelly, Lauren ^a   Shigematsu, Hirokazu ^c   Johnson, Leisa ^d   Akashi, Koichi ^c   Tuveson, David A ^e   Jacks, Tyler ^f,g   Gilliland, D Gary ^a,c,g,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d EXELIXIS INC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INTERFERON; K RAS PROTEIN; METHYLCELLULOSE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION; GENOTYPE; HEMATOPOIETIC SYSTEM; IMMUNOBLOTTING; MOUSE; MUTATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE K RAS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ADENOMA; ANIMAL; BONE MARROW TRANSPLANTATION; CELL CULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; MOUSE STRAIN; NEOPLASM; ONCOGENE RAS; PAPILLOMA; PATHOLOGY; PROMOTER REGION; TRANSGENIC MOUSE;

ADENOMA; ALLELES; ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; PAPILLOMA; PHENOTYPE; PROMOTER REGIONS (GENETICS);

EID: 85047690606     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20476     Document Type: Article

References (73)

1. Higuchi, M., et al. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 1:63-74.
2. Grisolano, J.L., Wessel schmidt, R.L., Pelicci, P.G., and Ley, T.J. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood. 89:376-387.
3. He, L.Z., et al. 1997. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 94:5302-5307.
4. Brown, D., et al. 1997. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 94:2551-2556.
5. Kelly, L.M., and Gilliland, D.G. 2002. Genetics of myeloid leukemias. Annu. Rev. Genomics Hum. Genet. 3:179-198.
6. Gilliland, D.G. 2001. Hematologic malignancies. Curr. Opin. Hematol. 8:189-191.
7. Hingorani, S.R., and Tuveson, D.A. 2003. Ras redux rethinking how and where Ras acts. Curr. Opin. Genet. Dev. 13:6-13.
8. Bar-Sagi, D. 2001. A Ras by any other name. Mol. Cell. Biol. 21:1441-1443.
9. Scheele, J.S., Ripple, D., and Lubbert, M. 2000. The role of ras and other low molecular weight guanine nucleoride (GTP)-binding proteins during hematopoietic cell differentiation. Cell. Mol. Life Sci. 57:1950-1963.
10. Shields, J.M., Pruitt, K., McFall, A., Shaub, A., and Der, C.J. 2000. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10:147-154.
11. Ellis, C.A., and Clark, G. 2000. The importance of being K-Ras. Cell. Signal. 12:425-434.
12. Beaupre, D.M., and Kurztock, R. 1999. RAS and leukemia: from basic mechanisms to gene-directed therapy J. Clin. Oncol. 17:1071-1079.
13. Reuter, C.W., Morgan, M.A., and Bergmann, L. 2000. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 96:1655-1669.
14. Gilliland, D.G., and Griffin, J.D. 2002. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:1532-1542.
15. Beghini, A., et al. 2000. C-kit mutations in core binding factor leukemias. Blood. 95:726-727.
16. Eguchi, M., et al. 1999. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 93:1355-1363.
17. Liu, Q., et al. 2000. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 19:1827-1838.
18. Papadopoulos, P., Ridge, S.A., Boucher, C.A., Stocking, C., and Wiedemann, L.M. 1995. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 55:34-38.
19. Golub, T.R., Barker, G.F., Stegmaier, K., and Gilliland, D.G. 1996. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Curr Top. Microbiol. Immunol. 211:279-288.
20. Kelly, L.M., et al. 2002. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 99:310-318.
21. Million, R.P., Aster, J., Gilliland, D.G., and Van Etten, R.A. 2002. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood. 99:4568-4577.
22. Cichowski, K., and Jacks, T. 2001. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 104:593-604.
23. Shannon, K.M., et al. 1994. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med. 330:597-601.
24. Jacks, T., et al. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 7:353-361.
25. Largaespada, D.A., Brannan, C.I., Jenkins, N.A., and Copeland, N.G. 1996. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet. 12:137-143.
26. Bollag, G., et al. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12:144-148.
27. + cells. J. Exp. Med. 185:1337-1347.
28. Darley, R.L., et al. 2002. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood. 100:4185-4192.
29. + cells. Br. J. Haematol. 102:289.
30. MacKenzie, K.L., Dolnikov, A., Millington, M., Shounan, Y., and Symonds, G. 1999. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood. 93:2043-2056.
31. Hawley, R.G., Fong, A.Z., Ngan, B.Y., and Hawley, T.S. 1995. Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene. 11:1113-1123.
32. Dunbar, C.E., Crosier, P.S., and Nienhuis, A.W. 1991. Introduction of an activated RAS oncogene into murine bone marrow lymphoid progenitors via retroviral gene transfer results in thymic lymphomas. Oncogene Res. 6:39-51.
33. Mangues, R., Symmans, W.F., Lu, S., Schwartz, S., and Pellicer, A. 1996. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene. 13:1053-1063.
34. Sinn, E., et al. 1987. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 49:465-475.
35. Song, W.J., et al. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23:166-175.
36. Quon, K.C., and Berns, A. 2001. Haplo-insufficiency? Let me count the ways. Genes Dev. 15:2917-2921.
37. Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. 1995. Inducible gene targeting in mice. Science. 269:1427-1429.
38. Jackson, E.L., et al. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:3243-3248.
39. Johnson, L., et al. 1997. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11:2468-2481.
40. Johnson, L., et al. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410:1111-1116.
41. Schwaller, J., et al. 1998. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17:5321-5333.
42. Miyamoto, T., et al. 2002. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev. Cell. 3:137-147.
43. Akashi, K., Traver, D., Miyamoto, T., and Weissman, I.L. 2000. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 404:193-197.
44. Deguchi, K., et al. 2003. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding morif and TIF2-mediated recruitment of CBP. Cancer Cell. 3:259-271.
45. Daley, G.Q., Van Etten, R.A., and Baltimore, D. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:824-830.
46. Tomasson, M.H., et al. 2000. Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581. J. Clin. Invest. 105:423-432.
47. Nguyen, M.H., Ho, J.M., Beattie, B.K., and Barber, D.L. 2001. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J. Biol. Chem. 276:32704-32713.
48. Neshat, M.S., Raitano, A.B., Wang, H.G., Reed, J.C., and Sawyers, C.L. 2000. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell. Biol. 20:1179-1186.
49. Dierov, J., Xu, Q., Dierova, R., and Carroll, M. 2002. TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood. 99:1758-1765.
50. Sternberg, D.W., et al. 2001. The TEL/PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood. 98:3390-3397.
51. Schwaller, J., et al. 2000. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell. 6:693-704.
52. Sattler, M., et al. 2002. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 1:479-492.
53. Tsurumi, S., et al. 2002. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am. J. Hematol. 71:131-133.
54. Mavrogianni, D., et al. 2002. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. Int. J. Hematol. 75:394-400.
55. Gaidano, G., Guerrasio, A., Serra, A., Rege-Cambrin, G., and Saglio, G. 1994. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia. 8:S27-S29.
56. Gaidano, G., et al. 1997. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes Cancer. 19:250-255.
57. Yuspa, S.H. 1998. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. J. Dermatol. Sci. 17:1-7.
58. Leder, A., Kuo, A., Cardiff, R.D., Sinn, E., and Leder, P. 1990. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. U. S. A. 87:9178-9182.
59. Nedergaard, T., Guldberg, P., Ralfkiaer, E., and Zeuthen, J. 1997. A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes: mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma. Int. J. Cancer. 71:364-369.
60. Schneider, A., Zhang, Y., Guan, Y., Davis, L.S., and Breyer, M.D. 2003. Differential, inducible gene targeting in renal epithelia, vascular endothelium, and viscera of Mx1Cre mice. Am. J. Physiol. Renal Physiol. 284:F411-F417.
61. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:593-602.
62. Palmero, I., Pantoja, C., and Serrano, M. 1998. p19ARF links the tumour suppressor p53 to Ras. Nature. 395:125-126.
63. Ferbeyre, G., et al. 2002. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22:3497-3508.
64. Guerra, C., et al. 2003. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 4:111-120.
65. Sebti, S.M., and Hamilton, A.D. 2000. Farnesyltransferase and geranylgeranyltransferase 1 inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19: 6584-6593.
66. Ahmadian, M.R. 2002. Prospects for anti-ras drugs. Br. J. Haematol. 116:511-518.
67. White, M.A., et al. 1995. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 80:533-541.
68. Khosravi-Far, R., et al. 1996. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell. Biol. 16:3923-3933.
69. Rodriguez-Viciana, P., et al. 1997. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 89:457-467.
70. Hamad, N.M., et al. 2002. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16:2045-2057.
71. Umanoff, H., Edelmann, W., Pellicer, A., and Kucherlapati, R. 1995. The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. U. S. A. 92:1709-1713.
72. Ise, K., et al. 2000. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene. 19:2951-2956.
73. Koera, K., et al. 1997. K-ras is essential for the development of the mouse embryo. Oncogene. 15:1151-1159.